Compare Uranium Energy Corp (UEC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uranium Energy Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Uranium Energy Corp trades at $11.43 (market cap $5.67B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| UEC | XBI | |
|---|---|---|
Market Cap | $5.67B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $20.14 | $164.28 |
52-Week Low | $9.04 | $86.92 |
Enterprise Value | $5.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UEC trades at $11.36, down 0.18% on the day, with a bullish technical signal driven by moving averages despite a neutral oscillator reading. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and faces significant profitability challenges with a negative net income margin of -513.24%. Recent news highlights insider selling and optimistic long-term uranium market forecasts.
Outlook hinges on uranium price recovery and production ramp-up, but risks include persistent losses, high valuation multiples, and execution delays. Analyst consensus is strongly bullish with 87.5% buy ratings, though fundamentals warrant caution due to cash burn and competitive pressures.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
